{"Clinical Trial ID": "NCT00193037", "Intervention": ["INTERVENTION 1:", "Arm A -Doxorubicin liposomal then Docetaxel", "Doxorubicin liposomal (Arm A)", "Doxorubicin liposomal 40 mg/m2 IV day 1 over one hour, repeated q 28 days per peripheral vein or central venous access. This will define a cycle.", "Patients with progression of liposomal doxorubicin were eligible for Docetaxel therapy, provided that the patient still met the criteria for laboratory eligibility and performance evaluation.", "INTERVENTION 2:", "The B arm - Docetaxel then liposomal doxorubicin", "Docetaxel weekly 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by a week of rest, administered over a 28-day cycle. This dosing regimen will define a cycle.", "Patients with progression on Docetaxel were eligible for treatment with liposomal doxorubicin, provided that the patient still met the criteria for laboratory eligibility and performance evaluation."], "Eligibility": ["Incorporation criteria:", "To be included in this study, you must meet the following criteria:", "Metastatic breast cancer confirmed by biopsy", "\u2022 Prior adjuvant/neoadjuvant treatment is allowed", "A Measurable Disease", "\u2022 Capable of carrying out activities of daily life with minimum assistance", "\u2022 Aged 18 or over", "\u2022 Sensitivity of bone marrow, liver and kidneys", "Normal heart function", "Written consent with knowledge of the case", "- Exclusion criteria:", "You may not participate in this study if any of the following applies to you:", "Pre-existing moderate peripheral neuropathy", "\u2022 History of major heart disease", "- Meningated metastases.", "Previous chemotherapy for metastatic breast cancer", "No measurable disease (including bone only, pleural effusion, etc.)", "I was treated with Herceptin.", "Pregnant or lactating women.", "Note: There are other inclusion and exclusion criteria. The study centre will determine if you meet all the criteria. If you are not eligible for the trial, the study staff will explain the reasons. If you are eligible, the study staff will explain the trial in detail and answer any questions you may have."], "Results": ["Performance measures:", "Overall response rate (AR), the percentage of patients receiving an objective benefit from treatment", "The complete response is the total disappearance of a clinically and radiologically detectable disease for at least 4 weeks. The partial response is a reduction of at least 50% of all measurable lesions measured by the product of perpendicular diameters of the largest size of the tumour, without new lesions appearing for at least 4 weeks.", "Time limit: 18 months", "Results 1:", "Title of the arm/group: Arm A -Doxorubicin liposomal then Docetaxel", "Description of the arm/group: Liposomal Doxorubicin (Arm A)", "Doxorubicin liposomal 40 mg/m2 IV day 1 over one hour, repeated q 28 days per peripheral vein or central venous access. This will define a cycle.", "Patients with progression of liposomal doxorubicin were eligible for Docetaxel therapy, provided that the patient still met the criteria for laboratory eligibility and performance evaluation.", "Total number of participants analysed: 42", "Type of measurement: Number", "Unit of measure: percentage of patients 28 (16 to 42)", "Results 2:", "Title of the arm/group: Bras B - Docetaxel then Doxorubicin liposomal", "Docetaxel weekly 36 mg/m2 IV over 30 minutes on days 1, 8 and 15 followed by a week of rest, administered over a 28-day cycle. This dosing schedule will define a cycle.", "Patients with progression on Docetaxel were eligible for treatment with liposomal doxorubicin, provided that the patient still met the criteria for laboratory eligibility and performance evaluation.", "Total number of participants analysed: 44", "Type of measurement: Number", "Unit of measure: percentage of patients 31 (18 to 45)"], "Adverse Events": ["Undesirable Events 1:", "Total: 18/50 (36.0 per cent)", "Hypotension 0/50 (0.00 %)", "Bradycardia 0/50 (0.00 %)", "- Cardiac arrest 1/50 (2.0%)", "Diarrhoea 2/50 (4.0%)", "Abdominal pain 1/50 (2.0%)", "Haemorrhage - GI 1/50 (2.0%)", "- Vomiting 0/50 (0.00 %)", "- Nausea 0/50 (0.00 %)", "Dehydration 0/50 (0.00 %)", "- Diverticular Abscesses 1/50 (2.0%)", "- Thrive failure 1/50 (2.0%)", "- Fever 0/50 (0.00 %)", "Adverse Events 2:", "Total: 22/52 (42.31 per cent)", "Hypotension 1/52 (1.92%)", "Bradycardia 1/52 (1.92%)", "- Cardiac arrest 0/52 (0.00 %)", "Diarrhoea 0/52 (0.00 %)", "Abdominal pain 0/52 (0.00 %)", "Haemorrhage - GI 1/52 (1.92%)", "- Vomiting 1/52 (1.92%)", "Nausea 1/52 (1.92%)", "Dehydration 1/52 (1.92%)", "= Miscellaneous abscess 0/52 (0.00 %)", "- Thrive failure 0/52 (0.00 %)", "Fever 1/52 (1.92%)"]}